- MPI’s Drug Response Predictor (DRP) can generate new and unique clinically relevant gene signatures – a strong complementary drug development tool
- TD2 is an oncology drug development company that customizes clinical trial design and execution for its customers by applying rigorous and high-throughput translational preclinical development, with best in class regulatory and clinical expertise.
Hoersholm, Denmark and Scottsdale, Ariz., USA- April 3, 2014 – Medical Prognosis Institute A/S (MPI) – a Danish company and Translational Drug Development LLC (TD2) based in Scottsdale, Arizona, today announced a strategic collaboration offering a proprietary service that defines which initial clinical indication would most likely lead to drug approval. “This technology can dramatically increase the probability of early clinical success” said Dr. Stephen Gately, CEO for TD2.
The use of these data is supported by strategic counselling from highly experienced translational experts focused on rapid approval. “The collaboration with TD2 is a fantastic opportunity for MPI to integrate our technology in the highly professional TD2 team” said Peter Buhl Jensen, CEO for MPI.
“I believe there is great synergy between MPI and TD2 services. These companies share the goal of providing data and clinically relevant insight to the global pharmaceutical and biotech industries as well as leading academic institutions, to accelerate oncology drug development” said Dr. Daniel Von Hoff, Chief Development Officer for TD2.
MPI was founded to improve the efficacy of cancer drugs through its Multi Biomarker technology called Drug Response Predictor (DRP). DRP is a validated, unique Multi Biomarker built on an algorithm from Big Data derived from human cancer tissue. DRP can be added to and will strengthen existing tools already being used in the drug development field.
MPI has incorporated in Arizona (MPI Inc.) and will establish a laboratory in the TD2 facilities to execute on joint collaborations in a capital efficient manner.
TD2 is an oncology drug development company that has facilities for the preclinical and clinical testing of candidate cancer drugs and treatments, as well as expertise in regulatory affairs. For preclinical studies, TD2 has more than 200 established models of human cancer. TD2 has performed early-mid phase clinical studies on over 400 new anticancer agents and has worked with more than 350 biotech and pharmaceutical companies worldwide. TD2 has an unmatched access to patients for clinical trials.
For further information please contact
Stephen Gately, CEO
email: [email protected]
Peter Buhl Jensen, CEO
e-mail: [email protected]
Mobil: +45 21 60 89 22
Certified Advisor to MPI: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark